novel recombinant vaccines for new indications n.
Skip this Video
Loading SlideShow in 5 Seconds.. PowerPoint Presentation
Download Presentation

0 Vues Download Presentation
Télécharger la présentation

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Novel Recombinant Vaccines for New Indications Creating Lucrative Opportunities in the Global Market A new study by the company titled 'Recombinant Vaccines Market: Global Industry Analysis 2013- 2017 and Opportunity Assessment 2018-2028', has listed out the key points being considered by Recombinant Vaccines companies to emerge and stay sustainably profitable in the long run in the Recombinant Vaccines market. The APEJ Recombinant Vaccines market is expected to expand at a CAGR of close to 7%, and is expected to remain as a main sink market for revenues. Western Europe is expected to remain as the main source market for Recombinant Vaccines, as most of the Recombinant Vaccines facilities are located in this region. However, with the increasing demand optimized & sustainable healthcare in countries such as China and India, and various countries of Asia Pacific and Middle-East, is fueling the growth of Recombinant Vaccines market. The report finds that there is an increasing focus on improving accessibility to recombinant vaccines. Vaccines are needed by 80% of the population and less than 20% has access to them. Vaccines are becoming an engine of growth for the pharmaceutical industry and given greater focus on preventive healthcare. However, there exists huge demand gap for vaccines demand and supply across the world. Newer and faster vaccines are entering the market however at and inflated pricing. Until and unless it is listed with providers such as Global Vaccines Alliance Imitative (GAVI) or the Bill and Melinda Gates Foundation, their access is limited in the developing

  2. countries The World Health Organization has noted that 60 vaccines are in shortfall in terms of availability in developing countries For More Details, Request to View a Sample Copy of This Report @ UNICEF, GAVI and PAHO are focusing on emerging countries for boosting availability of recombinant vaccines at low subsidized rates. Three main strategies followed by these organizations are partnerships with emerging economies and local manufacturers, if any; accelerated uptake and differentiated pricing; and improving cold chain facilities for better supply chain management Hospitals, private clinics & dispensaries, retail pharmacies & others distributing Recombinant Vaccines are the primary point of contact for patients experiencing infectious disease and others. Private clinics & dispensaries sub-segment under the end users segment for Recombinant Vaccines market, accounted for over 40% revenue share in the overall Recombinant Vaccines market in 2017. Growing demand for cost-effective diagnostic options success in clinical studies for developing a Recombinant Vaccines is expected to fuel the growth of the global Recombinant Vaccines market over the forecast period. Activities across the Recombinant Vaccines manufacturers are acquisitions, collaborations, sharing and product development. The top activity associated with Recombinant Vaccines

  3. manufacturers is joint collaboration with various organizations in order to spread awareness, further development, and promote the efficiency of Recombinant Vaccines. Rising focus on cost-effective diagnosis using Recombinant Vaccines is expected to boost the growth of the Recombinant Vaccines market. Recombinant Vaccines manufacturing companies focusing on spreading awareness about Recombinant Vaccines and marketing Recombinant Vaccines through campaigns and joint research studies is expected fuel the growth of the Recombinant Vaccines market during the forecast period. However, Recombinant Vaccines could experience stiff competition from alternative procedures and modalities that are well established and adopted by healthcare providers. Development of recombinant vaccines and commercial production is a complex procedure. Lead time required in production of a commercial lot of vaccines ranges from few months to several years depending on the complexity of vaccine composition, manufacturing process complexity, etc. It has been noted that to get a vaccine into the market it takes roughly about twelve years. Most important recombinant vaccines have entered the market in the last decade. The pipeline though strong marks presence of just few players which indicates tough market entry for new smaller players. Quality check and production maintenance coupled with stockpiling and unpredictable demand worsens costing scenario. Read Comprehensive Overview with Methodology of Report @ Some of the key Recombinant Vaccines companies analyzed in this report titled Recombinant Vaccines market include GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG. About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers. Contact Us U.S. Office 616 Corporate Way, Suite 2-9018,

  4. Valley Cottage, NY 10989, United States T: +1-347-918-3531 F: +1-845-579-5705 Email: Web: